The biological response to cannabinoid agonist begins when the agonist-bound receptor activates G-protein G ␣ subunits, thus initiating a cascade of signal transduction pathways. For this reason, information about cannabinoid receptors/G-protein coupling is critical to understand both the acute and chronic actions of cannabinoids. This review focuses on these mechanisms, predominantly examining the ability of cannabinoid agonists to activate G-proteins in brain with agonist-stimulated [ 35 S]guanylyl-5 ′ -O-( ␥ -thio)-triphosphate ([ 35 S]GTP ␥ S) binding. Acute effi cacies of cannabinoid agonists at the level of G-protein activation depend not only on the ability of the agonist to induce a high affi nity state in G ␣ for GTP, but also to induce a low affi nity for GDP. When several agonists are compared, it is clear that cannabinoid agonists differ considerably in their effi cacy. Both WIN 55212-2 and levonantradol are full agonists, while ⌬ 9 -tetrahydrocannabinol is a weak partial agonist. Of interest, anandamide and its stable analog methanandamide are partial agonists. Chronic treatment in vivo with cannabinoids produces signifi cant tolerance to the physiological and behavioral effects of these drugs, and several studies have shown that this is accompanied by a signifi cant loss in the ability of cannabinoid receptors to couple to G-proteins in brain. These effects vary across different brain regions and are usually (but not always) accompanied by loss of cannabinoid receptor binding. Although the relationship between cannabinoid receptor desensitization and tolerance has not yet been established, these mechanisms may represent events that lead to a loss of cannabinoid agonist response and development of tolerance.
INTRODUCTION
When Howlett fi rst reported the existence of specifi c cannabinoid receptors, 1 the crucial discovery depended on the fact that cannabinoid agonists inhibited adenylyl cyclase through a G-protein-coupled mechanism. Therefore, it was clear from the beginning that these receptors were members of the G-protein-coupled receptor superfamily. Subsequent studies demonstrated that cannabinoid receptors were indeed coupled to effectors that were modulated by the G i/o class of G-proteins. [2] [3] [4] This fi nding was followed by cannabinoid receptor radioligand binding, 5 receptor localization, 6 and cloning and sequencing of the brain cannabinoid receptor CB 1 . 7 The cloning of a peripheral cannabinoid receptor, CB 2 , from spleen cells 8 showed that there are at least 2 major types of cannabinoid receptors. Both receptor types are typical of the 7 transmembrane-domain superfamily of receptors, with 44% homology between CB 1 and CB 2 receptors. CB 1 is larger than CB 2 , with an additional 72 amino acid residues in the N-terminal region, 15 additional residues in the third extracellular loop, and 13 additional residues in the C-terminal region. The highest degree of homology between CB 1 and CB 2 occurs in the transmembrane regions TM2, TM3, TM5, and TM6; of interest, the homology in other regions is not particularly striking.
From these fi ndings, it is clear that cannabinoid receptors operate by many of the same principles that govern the other receptors in this family of proteins. But cannabinoid receptors also have several properties that make them unique among G-protein-coupled receptors, at least at this stage of our understanding. For example, CB 1 receptors exist in brain at levels higher than most other G-protein-coupled receptors, 5 , 6 approaching levels observed for amino acid receptors. This fact not only demonstrates the importance of CB 1 receptors in regulating brain activity in a variety of ways, but also has importance in regulating the effi cacy of cannabinoid agonists.
Another unique aspect of cannabinoid receptors is the fact that their endogenous ligands represent a class of lipophilic compounds based on the general structure of modifi ed arachidonic acid derivatives. The fi rst of these compounds, arachidonyl ethanolamide or anandamide, was isolated in 1992, 9 followed later by other arachidonyl endogenous cannabinoids including arachidonyl glycerol. 10 Among endogenous agonists at G-protein-coupled receptors, anandamide As observed above, cannabinoid receptors share many of the same properties of G-protein coupling and activation as other members of the GPCR superfamily. For example, guanine nucleotides inhibit cannabinoid agonist binding in a manner typical of G-protein-coupled receptors. 5 Moreover, cannabinoid binding sites can be solubilized from membranes together with G-proteins, 11 and recent evidence suggests that multiple cannabinoid ligands can activate different populations of G-proteins. 12 Cannabinoid receptor activation of G-proteins in isolated membranes can be measured by agonist-stimulated [ 35 13 The technique was originally developed in purifi ed systems, [14] [15] [16] and in membranes from heart, 17 brain, 18 In cells, this increase in GTP ␥ S affi nity can be 100-to 300-fold. 22 In vivo, the ␣ subunit GTPase hydrolyzes GTP to GDP; however, in vitro , [ 35 S]GTP ␥ S is useful because it is resistant to hydrolysis. Although fi rst developed in isolated membranes, these same principles can be applied (with several technical changes) to brain sections to localize receptor activity in different brain regions. The development of [ 35 S]GTP ␥ S autoradiography represented the fi rst in vitro method to provide a neuroanatomical localization of a receptor-coupled intracellular signal transduction system. 23 The Scatchard plot in Figure 1 shows the dramatic effect of WIN 55212-2 on activation of G-proteins as measured by 24 The energy associated with this change in affi nity is largely responsible for activation of receptor-mediated signal transduction.
In brain membranes, cannabinoid-stimulated [ 35 S]GTP ␥ S binding is especially high because of the relatively large number of cannabinoid receptors in brain. 25 However, the number of receptors present does not always directly translate into a larger response because of the phenomenon of catalytic amplifi cation between receptors and G-proteins. Several studies have shown that one receptor can couple to many different G-proteins to amplify agonist response. For example, in brain, cannabinoid receptor coupling to G-proteins is relatively ineffi cient 26 , 27 : in striatum, each cannabinoid receptor activates only 3 G-proteins compared with 20 G-proteins for each and ␦ opioid receptor ( Table 1 ) . It is possible that this relatively low amplifi cation is related to the high number of CB 1 receptors; since these receptors exist in such high number in the brain, a high amplifi cation between the receptor and transducer may not be necessary. A detailed brain regional analysis of cannabinoid amplifi cation 27 showed that the amplifi cation between CB 1 receptors and G-proteins varied widely between regions, with the smallest amplifi cation factor of 2 in regions such as frontal cortex, cerebellum, and hippocampus, and the largest amplifi cation factor of 7 in hypothalamus ( Figure 2 ). These results suggest that different behavioral effects of cannabinoids that are mediated in different brain regions may be less related to the number of receptors present, but rather to the level of coupling between receptors and signal-transduction systems. Agonist-stimulated [ 35 S]GTP ␥ S binding can also be used to determine differences in agonist effi cacy at the level of G-protein activation. 26 , 28 Using this technique in brain membranes, 24 , 29 , 30 WIN 55212-2 and levonantradol are full agonists, while anandamide produces partial effi cacy, and ⌬ 9 -tetrahydrocannabinol ( ⌬ 9 -THC) is a weak partial agonist ( Figure 3 ). The discovery that anandamide is a partial agonist was surprising; traditionally, endogenous agonists in any neurotransmitter-receptor system are considered, by defi nition, full agonists. It is important to note that the lower effi cacy of anandamide is not related to the metabolic instability of anandamide, since its metabolically stable analog methanandamide also produces the same partial effi cacy as anandamide itself.
The effi cacies of both exogenous and endogenous cannabinoids in activating G-proteins is related not only to the drugs ability to convert G ␣ into a high affi nity state for GTP, but also to their ability to shift G ␣ into a low affi nity state for GDP. 24 This principle is illustrated in Table 2 , where the effi cacies of several cannabinoids (E max ) are related to their ability to shift G ␣ into low affi nity states for GDP in cerebellar membranes. In the basal state, [ 35 S]GTP ␥ S binding sites have 2 affi nity states for GDP, 33 nM and 1147 nM. Additions of agonists have no effect on the high affi nity GDP binding, but the effi cacies of various cannabinoid agonists are directly related to their ability to shift the GDP low affi nity state into even lower affi nity. For example, the full agonist WIN 55212-2 shifts the GDP affi nity from 1147 nM to 8210 nM, a decrease in affi nity of 7.1-fold. A low effi cacy partial agonist such as ⌬ 9 -THC produces very little effect on the GDP affi nity, decreasing affi nity from 1147 nM to 1330 nM (1.2-fold shift). As predicted from its moderate effi cacy, methanandamide produces a moderate change in the affi nity for GDP, decreasing affi nity from 1147 nM to 6570 nM (5.7-fold shift). These results confi rm that anandamide is simply unable to produce a maximal activation of G-proteins, either by shifting G ␣ into a high affi nity state for GTP, or shifting G ␣ into a low affi nity state for GDP. This phenomenon is not just observed at the level of G-protein activation but also in the ability of anandamide to inhibit adenylyl cyclase 31 and affect ion channel function. 32 , 33 Why an endogenous ligand such as anandamide does not produce full effi cacy at its receptor remains an unanswered question at this point. It is possible, however, that the relatively low effi cacy of anandamide is counteracted by the large number of CB 1 receptors present in brain. Classical pharmacology predicts that partial agonists will exhibit full effi cacy in the presence of a large receptor reserve, where less than full occupancy can produce a full agonist response.
There is a discrepancy in the actions of the CB 1 receptor antagonist SR141716A in [ 35 S]GTP ␥ S experiments 24 ; in rat cerebellar membranes, SR141716A is a neutral antagonist, with no effect on [ 35 S]GTP ␥ S binding except at E115 concentrations 10 000 times greater than its affi nity at CB 1 receptors ( Figure 3 ), while in CB 1 receptor-transfected cells, SR141716A is an inverse agonist, producing relatively potent inhibition of basal [ 35 S]GTP ␥ S binding. 34 The signal of inverse agonists to reduce spontaneous activity of G-proteins is directly related to the number of receptors present, so that the detection of such activity is much more straightforward in transfected cells than in normal brain membranes. This fact demonstrates that fi ndings of inhibition of basal [ 35 S]GTP ␥ S binding in brain membranes by high concentrations of cannabinoid antagonists should be interpreted with caution.
Cannabinoid receptor activation of G-proteins infl uences multiple effector systems. Cannabinoid inhibition of adenylyl cyclase has been demonstrated in several cell types, 1 , 35 , 36 and in brain membranes. 31 , 37 In addition to inhibiting adenylyl cyclase, cannabinoids have been shown to stimulate cAMP accumulation. 38 As with other receptors coupled to G i/o proteins, activation of CB 1 receptors decreases Ca 2+ conductance 32 , 39 and increases K + conductance. 40 Although beyond the scope of this review, retrograde signaling has been well documented as a mechanism of endogenous cannabinoid modulation of neuronal cell fi ring. 41 
CHRONIC EFFECTS OF CANNABINOIDS IN ACTIVATING G-PROTEINS
Chronic administration of cannabinoids to animals results in tolerance to many of the acute effects of ⌬ 9 -THC, including memory disruption, 42 decreased locomotion, 43 and analgesia. 44 Several groups have attempted to correlate behavioral tolerance with biochemical alterations, and several studies have shown that brain cannabinoid receptor levels usually decrease after prolonged exposure to agonists, 45 , 46 although some studies have reported increases 47 or no changes 43 in receptor binding in brain. Appropriate controls have demonstrated that downregulation of cannabinoid receptors is homologous, and not simply due to neurotoxicity. Differences among studies may depend on the treatment agonist used, brain region examined, or treatment time. Despite these contradictory reports in vivo, there is general agreement that relatively short exposure of transfected cells in culture with cannabinoid agonists produces signifi cant receptor internalization and traffi cking. 48 Another reason why reports of cannabinoid receptor downregulation have been contradictory is because receptor downregulation is only one consequence of receptor desensitization. For all G-protein-coupled receptors, the fi rst step in desensitization is uncoupling of the receptor from G ␣ , thus reducing the agonist response. Therefore, the best place to look for chronic agonist-induced changes in receptor function is at the coupling between receptors and G-proteins. Chronic ⌬ 9 -THC treatment produces signifi cant desen sitization of cannabinoid-activated G-proteins in several rat brain regions, as determined by cannabinoid-stimulated [ 35 S]GTP ␥ S autoradiography. 30 These studies showed signifi cant reduction in cannabinoid-stimulated [ 35 S]GTP ␥ S binding in virtually every brain region ( Figure 4 ), although the actual amount of desensitization varied across brain regions, with a maximum of 75% reduction in hippocampus. Moreover, the time course of the decrease in cannabinoid-stimulated [ 35 S]GTP ␥ S binding varied across brain re gions. 49 For example, the rate of desensitization was relatively fast in hippocampus, where signifi cant reductions in cannabinoid-stimulated [ 35 S]GTP ␥ S binding were observed after only 3 days of treatment with ⌬ 9 -THC. A slower rate of desensitization was observed in cerebellum, where 7 days of treatment was required to see signifi cant desensitization, while the slowest results were obtained in globus pallidus, where 14 days of chronic ⌬ 9 -THC treatment were required for signifi cant cannabinoid/ G-protein desensitization. Such brain regional variation is consistent with the fact that tolerance to chronic drug ex posure often develops at different rates for different behavioral effects. Other studies have confi rmed the reduction in cannabinoid-activated G-proteins in brain following chronic 51 and CP-55940. 53 Of interest, in a study comparing the chronic effects of ⌬ 9 -THC and WIN 55212-2, both agonists produced signifi cant reduction in cannabinoid-stimulated [ 35 S]GTP ␥ S binding throughout brain, with chronic ⌬ 9 -THC even producing somewhat more desensitization than chronic WIN 55212-2 in some brain regions, 51 despite the fact that WIN 55212-2 has more efficacy than ⌬ 9 -THC in activating G-proteins.
The relationship between in vivo tolerance and the uncoupling of cannabinoid receptors to G-proteins observed after chronic administration of cannabinoid agonists is not yet clear. 54 The phenomenon of tolerance is complex and involves not only specifi c cannabinoid receptor mechanisms, but also interactions between cannabinoid systems and other neurotransmitters in brain circuitry. Nevertheless, the loss of receptor/G-protein coupling represents a fundamental alteration of cannabinoid-induced signal transduction and is consistent with the loss of agonist response that characterizes cannabinoid tolerance.
